Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-14

Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) [Phase 3]

View source ↗

Summary

Clinical trial update for VRDN-003 in active Thyroid Eye Disease; the Phase 3 study is ongoing but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VRDN-003

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING